Project Inform fights the HIV and hepatitis C epidemics by assuring the development of effective treatments and a cure; supporting individuals to make informed choices about their health; advocating for quality, affordable health care; and promoting medical strategies that prevent new infections.
Project Inform created this series of three publications to address commonly asked questions and issues that people face as they come to terms with their diagnosis of HIV or AIDS and begin to address their health needs, including making decisions about starting HIV meds.
After you've tested positive (booklet 1 of 3)
This booklet helps guide individuals on basic things to do after finding out they're HIV-positive, with an emphasis on understanding HIV infection, getting into care, and finding a support network.
Considering treatment & your health care (booklet 2 of 3)
This booklet explores decision making about HIV health, from considering treatment to talking things out with a support network and doctors to thinking more broadly about personal health needs.
What you should know about when to start & what to use (booklet 3 of 3)
This booklet focuses on the issues related to taking HIV medications, including deciding when to start and what to use, planning ahead, considering how treatment may affect one's life, and finding an HIV-experienced doctor.
Project Inform Fact Sheets provide detailed information on specific treatments, common infections, and strategies for maintaining health. They are based on the most current information from the latest research in HIV and AIDS.
Taking a consumer advocate's approach to reporting on medical, governmental and regulatory issues, Project Inform's well-respected, comprehensive treatment journal provides information from the most recent studies, plus perceptive analysis on current AIDS treatment and research.
This award-winning web site makes it possible for anyone to obtain free, confidential information. The Project Inform web site includes regularly updated information and alerts, plus the full range of Project Inform publications described in this brochure.
A Reassuring Voice
1.888.HIV.INFO (1.888.448.4636, toll-free)
Monday - Friday, 10am - 4pm (Pacific Time)
Project Inform's operators live with or are impacted by HIV, and provide valuable insight and support to callers by answering questions about HIV care and making referrals to local services. We have been answering the phone since 1985 -- talking to tens of thousands of people living with HIV and those who care about them. We talk with people across the US about their health and how to live well with HIV/AIDS. Messages can be left and will be returned.
Project Inform's Public Policy program seeks to protect and expand access to quality health care and treatment for people living with HIV/AIDS and/or hepatitis C. Over the past 25 years, we have advocated on behalf people with HIV to receive more inclusive services through federal and California state programs, such as the Ryan White CARE Act, ADAP, Medicaid, Medicare and Medi-Cal, among many others.
HIV Treatment and Research Advocacy
Throughout our history, Project Inform has worked to accelerate the pace of discovery in the HIV field. We continue to provide a community voice to inform regulatory and legislative bodies and the national and international research processes. We continue to partner with researchers in government, academia, the community and industry to ensure community needs are met and research is conducted in a timely and ethical manner.
All services and information are provided to our constituents nationally and internationally free of charge. More than ever, your support makes a difference in our ability to maintain these programs and to meet the information and education needs of the communities affected by HIV and AIDS.
To volunteer, to make a donation or a pledge, or to receive more information on ways to support Project Inform (including making a gift through your will or estate), follow the above links or please call 415.558.8669.
1375 Mission Street
San Francisco, CA 94103-2621
HIV Health InfoLine:
Monday through Friday, 10 am - 4 pm, Pacific Time
1.888.HIV.INFO (1.888.448.4636, toll-free)
Categories Covered:HIV Treatments in Development, Adverse Events, Comorbidities, and HIV, First-Line HIV Treatment, HIV Policy and Advocacy, Providing Quality HIV Care, FDA-Approved HIV Medications, HIV Treatment Strategies, Dolutegravir (Tivicay), Raltegravir (Isentress), PrEP (HIV Pre-Exposure Prophylaxis), HIV Education and Risk Management, HIV Epidemiology, Tipranavir (Aptivus), Darunavir (Prezista), HIV Case Management and Social Work, HIV Care and Services Outside the US, Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), HIV Prevention Methods, Managing Long-Term HIV Survivors, Maraviroc (Selzentry, Celsentri), Managing HIV Drug Resistance, HIV Basic Science and Pathogenesis, PEP (HIV Post-Exposure Prophylaxis), Switching or Stopping HIV Treatment, Abacavir/Dolutegravir/Lamivudine (Triumeq), Nelfinavir (Viracept), Efavirenz (Sustiva, Stocrin), Rilpivirine (Edurant), Meeting the Costs of HIV Care, Emtricitabine/Rilpivirine/Tenofovir Alafenamide (Odefsey), Nevirapine (Viramune), Enfuvirtide (T-20, Fuzeon), Atazanavir (Reyataz), Emtricitabine (FTC, Emtriva), Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla), Stavudine (d4T, Zerit), Didanosine (ddI, Videx)
"Helping People Access PrEP: A Frontline Provider Manual on PrEP Research, Care and Navigation" provides a wide range of information to aid the daily work that frontline staff engage in to support PrEP access and adherence.
A 12-year analysis of the large NA-ACCORD cohort showed that more than half of those who could use a statin to treat their cardiovascular diseasehad not received a prescription for it.
"Without early and consistent partnership with the community in our efforts to incrementally develop a cure for HIV we may never achieve what people with HIV most hope a cure will offer them."
A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...
"It is critical that patients and patient advocates work closely with medical, public health and health economics experts to speak out about our nation's ability to respond to viral hepatitis," Project Inform states.
Hepatitis C Infection and People Who Inject Drugs is a new resource for medical providers aimed at improving the health of people who inject drugs.
A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma.
The Swiss HIV Cohort Study presented additional data at this year's International AIDS Conference showing that life expectancy has increased another 34 years for a person who is on HIV treatment and in care.